Science, medicine, and the future: Pharmacogenetics
- 8 April 2000
- Vol. 320 (7240) , 987-990
- https://doi.org/10.1136/bmj.320.7240.987
Abstract
MethodsWe compiled the article from the published literature, information presented at scientific meetings, our own published research work, and information gained from working with the pharmaceutical industry on drugs in development.This publication has 9 references indexed in Scilit:
- Extension of a Pilot Study: Impact From the Cytochrome P450 2D6 Polymorphism on Outcome and Costs Associated With Severe Mental IllnessJournal of Clinical Psychopharmacology, 2000
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- PharmacogeneticsBritish Medical Bulletin, 1999
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998
- The cost of adverse drug reactions.1997
- Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanismsPharmacogenetics, 1996
- Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.Proceedings of the National Academy of Sciences, 1993
- Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineThe Lancet, 1993
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990